Cerebrovascular disease and mortality in hospitalized patients with COVID-19 in a Latin American country, Peru.

Accidente cerebrovascular y mortalidad en pacientes hospitalizados con COVID-19 en un país de Latinoamérica, Perú.

Marla Gallo-Guerrero [1,a], Miguel A. Vences [2,b], Jessica Hanae Zafra-Tanaka [3], Diego Galindo [4,b], Maira Saavedra [4,b], Cynthia Zevallos [5,c]

SUMMARY

Objective: This study aimed at: 1) Assessment of the frequency of stroke and related mortality rate in patients hospitalized for COVID-19 in two major hospital referral centers in Peru; 2) Exploration of factors associated to mortality and dependency in these patients; 3) Comparisons of frequency of admissions of stroke patients and reperfusion treatments in similar periods of time prior to (2019) and during the pandemia occurrence. ***Material and Methods:*** A retrospective cohort study was conducted in two of the largest referral hospital centers for COVID-19 in Peru. The study included patient victims of stroke and COVID-19, hospitalized between April and August 2020. Demographic, clinical and laboratory data, radiological findings, and severity levels measured by the NIHSS scale were collected. Poisson regression models to evaluate associated factors to mortality and dependency were applied. ***Results:*** A 31% reduction of admissions for stroke, and of 81% of intravenous reperfusion treatment, respectively, were found in 2020 when compared with 2019. 1.37% of the patients with COVID-19 experienced a stroke, with an overall mortality rate of 40.6%, and a dependency rate of 68.3% at discharge time (Rankin > 2). An age increase of 10 years was found in mortality, associated with a 29% increase in mortality risk. As well, having hypertension, chronic kidney disease, inflammatory markers (D dimer and ferritin) and the severity of the stroke were associated with mortality. Finally, the severity of stroke, lymphopenia, and inflammatory markers (D dimer and fibrinogen) were associated with greater risk of dependency. ***Conclusions:*** The care system of stroke patients was affected by the COVID-19 pandemic in two of Perú's major public hospitals. There was a decrease in admissions and reperfusion treatments of stroke cases, and 1.37% of patients with COVID-19 presented a stroke. Age, hypertension, chronic kidney disease, inflammatory markers and severity of stroke were associated with mortality in these patients.

KEYWORDS: Stroke, COVID-19, mortality, Tissue Plasminogen Activator, Peru.

RESUMEN

Objetivo: Los objetivos del presente trabajo fueron: 1) Evaluar la frecuencia de accidente cerebrovascular (ACV) y de la tasa de mortalidad en pacientes hospitalizados por COVID-19 en dos importantes centros hospitalarios de referencia en Perú, 2) Exploración de factores asociados a mortalidad y dependencia en estos pacientes, 3)

1   Servicio de Neurología, Clínica Ricardo Palma. Lima, Perú.
2   Servicio de Neurología, Hospital Edgardo Rebagliati Martins. Lima, Perú.
3   Escuela de Medicina, Universidad Científica del Sur, Lima, Perú.
4   Servicio de Neurología, Hospital Guillermo Almenara Irigoyen. Lima, Perú.
5   University of Iowa Hospitals and Clinics. Iowa City, Iowa, USA.
a   Endovascular neurologist.
b   Neurologist.
c   Fellow in Endovascular Neuroradiology.

Comparar la frecuencia de admisiones de pacientes con ACV y de los tratamientos de reperfusión en tiempo de pandemia y en periodos previos (2019). ***Material y Métodos:*** Se realizó un estudio retrospectivo en dos de los mayores centros hospitalarios de referencia en Perú, incluyendo pacientes con ACV y COVID-19 hospitalizados entre abril y agosto del 2020. Se recolectó información demográfica, clínica y de laboratorio, hallazgos radiológicos y niveles de severidad medidos por la escala NIHSS, y se utilizó un modelo de regresión de Poisson para evaluar los factores asociados a mortalidad y dependencia. ***Resultados:*** Se encontró una disminución del 31% de admisiones hospitalarias de pacientes con ACV (ictus) y del 81% de los tratamientos de reperfusión endovenosa en el 2020 con respecto al 2019. Un 1.37% de pacientes con COVID-19 experimentaron ACV, con una mortalidad global de 40.6% y dependencia al alta del 58.3% (rankin >2). Un incremento de 10 años en edad se asoció con un aumento del 29% en el riesgo de mortalidad. Hipertensión arterial, enfermedad renal crónica, marcadores inflamatorios (Dímero D y ferritina) y la gravedad del ictus se encontraron asociados con mortalidad. La gravedad del ictus, la linfopenia y los marcadores inflamatorios (Dimero D y fibrinógeno) estuvieron asociados a un mayor riesgo de dependencia. ***Conclusión:*** El sistema de atención de ACVs se vio afectado por la pandemia del COVID-19 en dos de los centros hospitalarios públicos más grandes del Perú. Se encontró una disminución en las admisiones hospitalarias y en los tratamientos de reperfusión de estos pacientes durante la pandemia. Edad, hipertensión, enfermedad renal crónica, marcadores inflamatorios y gravedad del ictus fueron factores asociados con la mortalidad de pacientes con COVID-19 y ACV.

PALABRAS CLAVE: Accidente Cerebrovascular, COVID-19, mortalidad, activador de tejido plasminógeno, Perú

INTRODUCTION

One of the most severe neurological manifestations of acute respiratory syndrome coronavirus 2 (SARS-COV-2) is cerebrovascular disease (CVD). Reports suggest an association between COVID-19 and CVD, especially ischemic strokes, and less frequently cerebral venous thrombosis and hemorrhagic strokes. This can be explained by the association of coronavirus with a transient hypercoagulable state and disruption of endothelial function, especially in severe cases (1,2,3).

During the pandemic, different studies have shown that not all patients develop a severe form of the disease and stroke during infection with COVID-19. It has been reported an incidence of acute ischemic stroke in COVID-19 patients that ranges from 0.9% to 2.7%, with a moderate severity, high prevalence of large vessel occlusion (40.9%) and a high mortality rate (38%) (4,5). Similarly, healthcare racial/ethnic inequities have been unveiled during the pandemic (6). Elevated D-dimer, fibrinogen and the presence of antiphospholipid antibodies are prominent in COVID-19 patients with concomitant stroke. In Latin America, a study done in Bolivia found that age (>60y) and hypertension were independent risk factors for mortality (6). Finally, a systematic review found that patients with COVID-19 who experienced stroke, were more likely to be older, have pre-existing cardiovascular comorbidities, and a severe infection (7).

The determination of these risk factors in Latin American countries is important because it will allow prioritizing patients and deriving the necessary resources, since equipment and resources are scarce. For instance, even though the Peruvian government set up rules to contain the infection, like mandatory quarantine, Peru had one of the highest mortality rates in the world (8). It is necessary to have information on the current situation in Latin America on how the COVID-19 pandemic has influenced hospital care for stroke.

This study aims to assess the frequency and mortality of stroke on patients hospitalized for COVID-19 in two major referral centers in Peru. Additionally, to assess the associated factors to mortality in these patients. Finally, to compare the frequency of stroke admissions and reperfusion treatments during pandemic time with the same period in 2019.

MATERIAL AND METHODS

Study Design and Participants

An observational, retrospective cohort study was conducted in Guillermo Almenara Irigoyen and Edgardo Rebagliati Martins National Hospitals. These two medical centers are considered as national referral centers for patients with COVID-19, especially for the most severe COVID-19 cases.

All consecutive adult patients (18 years of age or older) who were admitted with stroke and COVID-19 between April and August 2020 were eligible for inclusion. We excluded patients who had the infection after a stroke.

The patients were considered COVID-19 cases following the recommendations of the Ministry of Public Health. (Ministerial resolution N 905-2020-MINSA Sanitary directive 122) Requiring a positive antigenic test or diagnostic serological test (ELISA, immunofluorescence, chemiluminescence) reactive to IgM or IgM/IgG to SARS-CoV-2 infection or a positive polymerase chain reaction test with nasopharyngeal swab (RT-PCR) to be considered positive cases of COVID-19. The standard test to confirm cases of COVID-19 was the molecular test, in situations where this test is not available, the SARS-CoV2 antigen detection test was considered a confirmatory test.

Data Collection

The information was collected from the electronic health care records including all the COVID-19 patients with stroke. A database was elaborated using Excel, and data entry was performed by neurologists and neurology residents trained in responsible conduct for research from both hospitals. We collected the following information: demographics, clinical, radiological findings and laboratory data (hemogram, coagulation, and inflammatory markers), and reason for admission. The type of stroke, affected cerebrovascular territory, severity of the stroke (estimated by the National Institute of Health Stroke Scale, NIHSS), and the reperfusion modality were recorded. We reported the reperfusion treatment, in-hospital complications, mortality, and length of hospital stay.

We use the NIHSS to assess stroke severity which includes 15 elements, and ranges from 0 to 42. We categorized as: minor stroke with a scale of 1-5; moderate stroke, 6 -14 and severe stroke > 15.

In order to estimate the number of stroke patients during 2019 and 2020, we included patients with ICD-10 codes 10 U07.1 and G45.8, G45,9, I63.0, I63.2, I63.3, I63.4, I63.5, I63.6, I63.9, I64, I67.9. The mortality rate was corroborated with the national information system of deaths of Perú.

The outcome was the functional status estimated by the modified Rankin scale (mRS) at discharge or the last evaluation for patients still admitted. This is a scale that measures the degree of disability in patients who have had a stroke. It ranges from 0 (No symptoms at all) to 6 (dead), and we considered scores greater than 2 as functional dependency.

Statistical analysis

Absolute and relative frequencies were used to describe categorical variables, while central tendency and dispersion measures were used for quantitative variables. To evaluate associated factors to mortality and dependency (mRS> 2) we fitted Poisson regression models with robust variance and adjusted for potential confounders (age and sex). The analyses were carried out using a level of significance of 5%. The mortality rate was calculated by estimating the frequency of deaths in COVID patients during the period of time of our study.

The statistical analysis was performed using Stata v14 (StataCorp LP, 2015. College Station, Texas, USA).

Ethical aspects

The study was approved by the Research Ethics Committee for COVID-19 of the Health Social Security - Essalud. Informed consent was not obtained because the information was collected from electronic clinical records and patients were not intervened. The principle of confidentiality was guaranteed in the whole process of the study, keeping the identity of the patients anonymous.

RESULTS

There were 101 patients with COVID-19 and stroke among the 7342 patients admitted with COVID-19 in the study sites (stroke incidence:1.4%). The median age was 75 years, ranging from 25 to 96 years, and 56.4% were males (table 1). About reperfusion treatments, only 6 patients received intravenous thrombolysis and none thrombectomy.

Before pandemic, between April and August 2019, there were 286 stroke admissions in both hospitals. Compared both periods of time, there was a 35% decrease in admissions of stroke before and after pandemic.

Regarding intravenous reperfusion treatment with rtPA, in 2019 there were 32 patients and in 2020 in the same period of time there were 6 with a reduction of 81% and no cases of thrombectomy were reported

in 2020 and 1 the previous year (Figure 1), 93% of the patients receive anti aggregating treatment and 5% anticoagulation.

The majority of patients (64.4%) with stroke and COVID-19 were hospitalized only for stroke without respiratory symptoms and 35.6% were admitted for acute respiratory distress. 13.9% of the patients that were admitted with respiratory symptoms developed stroke during hospitalization. Most of the patients had a confirmed diagnosis of COVID19 (84.7%) (table 2).


Figure 1. Comparative between 2019 and 2020 stroke patient's situation.

Table 1. Characteristics of hospitalized patients with COVID-19 and stroke (n=101)

Characteristics	N (%)
Age (years)*	75 (65-83)
Male	57 (56.4)
Comorbidities	
Hypertension (n=95)	52 (54.7)
Diabetes mellitus (n=95)	29 (30.5)
Chronic kidney disease (n=95)	10 (10.5)
Chronic heart failure (n=95)	8 (8.4)
Regular medication	
Antiplatelets	4 (4.0)
Anticoagulants	7 (6.9)
Antihypertensives	48 (47.5)
Antiarrhythmics (n=100)	11 (11.0)
Admission reason	
Acute respiratory distress	36 (35.6)
Stroke	65 (64.4)

Time from stroke onset to neurology consultation (n=81)	8 (5 - 24)
<6h	28 (34.6)
6-24h	22 (27.2)
24-48h	12 (14.8)
48-72	7 (8.6)
>72h	12 (14.8)
Length of stay (days)*	10 (4 - 21)

*Median (IQR)

Table 2. Stroke characteristics of hospitalized patients with COVID-19 and stroke

Characteristics	N (%)
Type of stroke (n=100)	
Ischemic stroke	93 (93.0)
Hemorrhagic stroke	6 (6.0)
Transient ischemic attack	1 (1.0)
Stroke severity	
NIHSS* (n=98)	9 (6 - 16)
Mild (<=5)	21 (21.4)
Moderate (6 to 14)	40 (40.8)
Severe (>=15)	37 (37.8)
Clinical presentation	
Motor deficit	82 (81.2)
Visual deficit	8 (7.9)
Headache	21 (20.8)
Alert impairment	9 (8.9)
Language compromise	37 (36.6)
Ataxia	6 (5.9)
Cranial nerve compromise	4 (4.0)
Seizures	1 (1.0)
Large-vessel occlusion	20 (19.8)
Vascular Territory of Acute Ischemic Lesions (n=93)	
Anterior territory	75 (80.7)
Posterior territory	17 (18.3)
Undetermined	1 (1.1)
TOAST (n=93)	
Large-artery atherosclerosis	20 (21.5)
Small-vessel occlusion	19 (20.4)
Cardioembolic	21 (22.6)
Stroke of undetermined etiology	33 (35.5)
Laboratory results	
Lymphocytes cel/uL (n=99)	1356 (900 - 1932)
Platelets cel/uL (n=99)	261000 (200000 - 355000)
Ferritin ng/mL (n=58)	465.5 (220.3 - 1061)

D-Dimer ug/mL (n=56)	2.11 (0.76 - 4.35)
Fibrinogen g/L (n=88)	4.25 (3.79 - 4.8)
Treatment (n=92)	
Thrombolysis	1 (1.1)
Antiaggregation	86 (93.5)
Anticoagulation	5 (5.4)
Outcome	
Rankin*	4 (3 - 6)
0	2 (2.0)
1	6 (5.9)
2	11 (10.9)
3	17 (16.8)
4	16 (15.8)
5	8 (7.9)
6 (deceased)	41 (40.6)

*Median (IQR)

Ischemic stroke was the most frequent (93%), followed by hemorrhagic stroke (6%) and transient ischemic attack (1%). The median number of hours passed between the onset of stroke symptoms and the first medical assessment of stroke was 8 hours (IQR: 5 to 24) and 13.9% of the patients developed stroke during hospitalization. Moderate to severe stroke (NIHSS >= 6) was found in 78.6% of the participants and mild strokes (NIHSS <5) was found in 21.4%.

According to the TOAST classification (acute ischemic stroke), 35.5% were of undetermined etiology, 22.6% were cardioembolic, 22.5% were large artery atherosclerosis, and small-vessel disease accounted for 20.4%. The most frequently affected vascular territory was the middle cerebral artery (79.6%), followed by vertebral and basilar territories (6.5% each).

The SMASH-U etiological classification was used for hemorrhagic stroke: 1 patient had a structural vascular lesion (rupture of an aneurysm of the posterior cerebral artery territory), 2 due to hypertensive cause and the other 4 had an indeterminate etiology. All of the patients with hemorrhagic stroke died.

During hospitalization, one-third of patients developed at least one complication (31/84). The most common complications were infectious (14/84), metabolic (12/84), and neurological (10/84). Ten patients presented neurological complications including: hemorrhagic transformation (4/10), cerebral edema, intracranial hypertension and increased cerebral infarction.

We found an overall mortality rate of 40.6% and a dependency rate at discharge of 68.3%. The mortality in the ischemic stroke group of patients was 36.6%.

When we explored the association between factors, we found that an increase in 10 years of age was associated with a 29% increase in the risk of mortality when adjusting by sex. In addition, after adjusting for age and sex, having hypertension and chronic kidney disease was associated with a 1.79 and 1.82-fold increased risk of mortality compared to those who did not have these conditions, respectively. The severity of stroke measured using NIHSS was associated with a 1.70-fold increased risk of mortality compared to those with non-severe stroke. Inflammatory markers such as D-dimer and Ferritin were also associated with higher mortality (table 3).

With regards to dependency, the severity of stroke was associated with a 1.85-fold increased risk of dependency compared to those with non-severe stroke when adjusting for age and sex. Also, lymphopenia and inflammatory markers (D-dimer and fibrinogen) were associated with greater risk of dependency (table 4).

Table 3. Associated factors to mortality in patients with stroke and COVID-19 (n=101)

Characteristics	Alive (n=60) n (%)	Deceased (n= 51) n (%)	p value	Prevalence Ratio (PR) (95% CI)	Adjusted RR (95% CI)
Age (years)*	70 (62 - 82)	77 (72 - 85)	0.006	**1.29 (1.02 - 1.62)**	**1.29 (1.02 - 1.63)**
Gender					
Female	26 (59.1)	18 (40.9)	0.995	REF	REF
Male	34 (59.6)	23 (40.4)		0.99 (0.61 - 1.59)	1.01 (0.64 - 1.61)
Hypertension (n=95)					
No	32 (74.4)	11 (25.6)	0.009	REF	REF
Yes	25 (48.1)	27 (51.9)		**2.03 (1.14 - 3.61)**	**1.79 (1.01 - 3.15)**
Diabetes mellitus (n=95)					
No	43 (65.2)	23 (34.8)	0.122	REF	REF
Yes	14 (48.3)	15 (51.7)		1.48 (0.91 - 2.41)	1.51 (0.93 - 2.43)
Chronic kidney disease (n=95)**					
No	54 (63.5)	31 (36.5)	0.083	REF	REF
Yes	3 (30.0)	7 (70.0)		**1.92 (1.17 - 3.15)**	**1.82 (1.07 - 3.08)**
Chronic heart failure (n=95)**					
No	53 (60.9)	34 (39.1)	0.709	REF	REF
Yes	4 (50.0)	4 (50.0)		1.28 (0.61 - 2.69)	1.25 (0.56 - 2.82)
Admission reason					
Acute respiratory distress	18 (50.0)	18 (50.0)	0.152	REF	REF
Stroke	42 (64.6)	23 (35.4)		0.71 (0.44 - 1.13)	0.71 (0.45 - 1.11)
Time from stroke onset to consultation (n=81)					
<=24h	10 (50.0)	10 (50.0)	0.269	REF	REF
>24h	39 (63.9)	22 (36.1)		0.72 (0.41 - 1.26)	0.73 (0.42 - 1.26)
LVO					
No	46 (56.8)	35 (43.2)	0.281	REF	
Yes	14 (70.0)	6 (30.0)		0.69 (0.34 - 1.42)	0.77 (0.37 - 1.59)
NIHSS (n=98)					
Not severe (<15)	42 (68.9)	19 (31.1)	0.047	REF	REF
Severe (>=15)	18 (48.6)	19 (51.4)		**1.65 (1.01 - 2.69)**	**1.70 (1.05 - 2.75)**
TOAST (n=93)					
Small-vessel occlusion	17 (89.5)	2 (10.5)	0.009	REF	REF
Large-artery atherosclerosis	15 (75.0)	5 (25.0)		2.38 (0.52 - 10.89)	2.57 (0.55 - 12.07)
Cardioembolic	9 (42.9)	12 (57.1)		**5.43 (1.38 - 21.36)**	**4.83 (1.23 - 18.93)**
Stroke of undetermined etiology	18 (54.5)	15 (45.5)		**4.32 (1.10 - 17.00)**	**4.28 (1.09 - 16.81)**
Complications (n=84)					
No	33 (62.3)	20 (37.7)	0.929	REF	REF
Yes	19 (61.3)	12 (38.7)		1.03 (0.58 - 1.81)	1.15 (0.65 - 2.05)
Severe lymphopenia (n=97)**					
No	55 (61.8)	34 (38.2)	0.062	REF	REF
Yes	2 (25.0)	6 (75.0)		**1.96 (1.21 - 3.18)**	1.61 (0.96 - 2.71)

Platelets (n=99)*	266500 (203000 - 371000)	235000 (190000 - 308000)	0.2724	0.99 (0.97 - 1.01)	1.00 (0.98 - 1.01)
Ferritin (n=58)					
<750	26 (68.4)	12 (31.6)	0.083	REF	REF
>=750	9 (45.0)	11 (55.0)		1.74 (0.94 - 3.23)	**1.94 (1.05 - 3.55)**
D dimer (n=56)					
<1	16 (88.9)	2 (11.1)	0.013	REF	REF
>=1	21 (55.3)	17 (44.7)		**4.03 (1.03 - 15.78)**	**3.99 (1.07 - 14.93)**
Fibrinogen (n=88)					
<4	18 (58.1)	13 (41.9)	0.885	REF	REF
>=4	34 (59.6)	23 (40.4)		0.96 (0.57 - 1.62)	1.02 (0.61 - 1.68)

*Ranksum test
**Fisher Exact test
Models adjusted by age and sex. Age was scaled to 10 for the regression models.

Table 4. Associated factors to dependency in patients with stroke and COVID-19 (n=60)

Characteristics	Independent (n=19) n (%)	Dependent (n= 41) n (%)	p value	Prevalence Ratio (PR) (95% CI)	Adjusted RR (95% CI)
Age (years)*	70 (61 - 82)	72 (63 - 81)	0.691	1.00 (0.90 - 1.12)	1.00 (0.99 - 1.01)
Gender					
Female	8 (30.8)	18 (69.2)	0.896	REF	REF
Male	11 (32.4)	23 (67.6)		0.98 (0.69 - 1.39)	0.98 (0.69 - 1.38)
Admission reason					
Acure respiratory distress	4 (22.2)	14 (77.8)	0.303	REF	REF
Stroke	15 (35.7)	27 (64.3)		0.83 (0.59 - 1.16)	0.83 (0.59 - 1.16)
Time from stroke onset to consultation (n=49)**					
<=24h	4 (22.2)	14 (77.8)	0.303	REF	REF
>24h	15 (35.7)	27 (64.3)		0.77 (0.52 - 1.15)	0.77 (0.51 - 1.15)
LVO**					
No	14 (30.4)	32 (69.6)	0.749	REF	REF
Yes	5 (35.7)	9 (64.3)		0.92 (0.60 - 1.43)	0.92 (0.59 - 1.42)
NIHSS					
Not severe (<15)	19 (45.2)	23 (54.8)	0.001	REF	REF
Severe (>=15)	0 (0.0)	18 (100.0)		**1.83 (1.38 - 2.41)**	**1.85 (1.39 - 2.45)**
TOAST (n=59)					
Small-vessel occlusion	10 (58.8)	7 (41.2)	0.01	REF	REF
Large-artery atherosclerosis	5 (33.3)	10 (66.7)		1.62 (0.82 - 3.19)	1.62 (0.82 - 3.20)
Cardioembolic	1 (11.1)	8 (88.9)		**2.16 (1.16 - 4.01)**	**2.12 (1.14 - 3.93)**
Stroke of undetermined etiology	2 (11.1)	16 (88.9)		**2.16 (1.19 - 3.92)**	**2.21 (1.22 - 4.01)**
Complications (n=52)					
No	10 (30.3)	23 (69.7)	0.929	REF	REF
Yes	5 (26.3)	14 (73.7)		1.06 (0.74 - 1.51)	1.05 (0.73 - 1.52)

Severe lymphopenia (n=57)**					
No	17 (30.9)	38 (69.1)	1	REF	REF
Yes	0 (0.0)	2 (100.0)		**1.45 (1.21 - 1.73)**	**1.45 (1.21 - 1.75)**
Platelets (n=58)*	277000 (218000 - 468000)	262000 (203000 - 366500)	0.6928	1.00 (0.99 - 1.01)	1.00 (0.98 - 1.01)
Ferritine (n=35)**					
<750	8 (30.8)	18 (69.2)	1	REF	REF
>=750	3 (33.3)	6 (66.7)		0.96 (0.56 - 1.65)	0.91 (0.53 - 1.55)
D dimer (n=37)					
<1	10 (62.5)	6 (37.5)	0.002	REF	REF
>=1	3 (14.3)	18 (85.7)		**2.29 (1.18 - 4.45)**	**2.30 (1.19 - 4.43)**
Fibrinogen (n=57)					
<4	10 (55.6)	8 (44.4)	0.002	REF	REF
>=4	5 (14.7)	29 (85.3)		**1.92 (1.12 - 3.29)**	**1.94 (1.13 - 3.32)**

*Ranksum test
**Fisher Exact test
Models adjusted by age and sex. Age was scaled to 10 for the regression models.

DISCUSSION

In our two-center observational study we described the characteristics of stroke patients with COVID-19. We observed a reduction of 31% in stroke patients admitted by emergency during the pandemic time (April - August) as compared to the previous year. Similarly, in Catalonia, Chicago, and Italy the number of code stroke activations decreased by 18%, 20% and 50% respectively during the pandemic (9). Also, Latin American countries like Brazil and Chile reported a decrease in the admission of all acute strokes. This can be explained by patients' reluctance to seek medical care during the pandemic due to the adaptation of social distancing practices, the fear of contagion of the population and subsequent avoidance of the overcrowded emergency departments. Additionally, due to the prioritization of the management of patients with COVID-19 over other conditions with the subsequent reallocation of resources (e.g., specialists such as neurologist providing care to patients with COVID-19 or reallocation of beds) and the reduced capacities of emergency services due to the burden of COVID-19 patients (10,11,12).

In the period of our study, 1.4% of the patients with COVID-19 presented a stroke. There have been reported an incidence of stroke in COVD-19 patients from 0.19% to 5.4% and by Klok et al. of 1.6% and 2.5% by Lodigiani et al., (13,14,15). Our study reported most of the cases were ischemic strokes.

These results are similar to the previously reported literature. Ghannam et al. that studied neurological manifestations in COVID 19 patients, reported 87.5% ischemic stroke, 5% cerebral venous thrombosis, 5% intraparenchymal hemorrhage, and 2.5% subarachnoid hemorrhage (16). It is hypothesized that patients with COVID-19 are at increased risk of cerebrovascular events, due to a systematic response by SARS-COV2 that lead to arterial and venous thrombotic complications, hypercoagulability, endothelial injury and venous stasis (17).

Only 32% of the patients arrived at the emergency room within 6 hours of having symptoms, 25% 6 to 24 hours and 36% after 24 hours to 92 hours, losing the possibility of intravenous or endovascular reperfusion treatment in the early window without the need of perfusion imaging. This might reflect a well-known old problem. In Peru, we lack an adequate pre-hospital system for stroke and there is poor recognition of stroke symptoms. Moreover, in Latin America it has been reported that only 3-15% of the population and 50% of health workers recognize at least one warning symptom of stroke. We have no data of the onset time of symptoms to CT scan and other times but it is likely that it has increased, because of the restriction of the transportation during the quarantine and COVID-19 screening procedures (18). During the pandemic, triage system underwent modifications, prioritizing if the patient had respiratory symptoms. The patients usually underwent brain and lung tomography in addition to

taking a sample for COVID antigen or PCR. Every patient was treated as COVID positive until the results were available which prolonged treatment times.

A large-vessel occlusion was found in 19.8% of cases, these results are lower than other studies carried out worldwide, in some of them this percentage is even doubled (19,20). However, we were able to perform complete vascular imaging studies in less than 40% of our patients. Also, based on the TOAST classification the predominant subtype was cryptogenic stroke in 33%, this predominance coincides with the studies carried out worldwide, some of them give even higher percentage like the 60% of their total cases (21).

Although the efficacy of mechanical thrombectomy has been demonstrated in South American countries (22), the only available treatment in public hospitals in Peru is intravenous thrombolysis. Despite this, we evidenced a significant decrease in the number of intravenous thrombolysis performed compared to 2019. The reduction of this reperfusion treatment was 81% (32 vs. 6), these percentages are much higher compared to similar studies carried out in other parts of the world, like in France, USA (Ohio, Kentucky, and Indiana) and Lyon where they observed 33.3%, 31% and 25% respectively fewer acute revascularization treatments during the month of March 2020 vs. their similar one in 2019, primarily related to reduced thrombolysis rates (23,24,25). Before the pandemic in Peru there were studies that reported 1-2% thrombolysis rates showing a problem that with the pandemic only got worse.

It has been described that COVID-19 patients have a greater stroke severity and poorer outcomes compared to historical series prior to the pandemic, 40.8% of patients had moderate impairment (NIHSS 10-15) and 37.8% severe compromise (NIHSS >15). (5) A preliminary report of a study carried out in a reference hospital in Peru showed an association between the presence of stroke and mortality in patients admitted for COVID-19 (RR = 1.49). They concluded that the presence of stroke is a poor prognostic factor in patients with COVID-19 (26). Previous studies conducted in Peru before the pandemic, reported a rate of 42-68% of patients with independence (mRS0-1) after thrombolysis. In our study only 18.8% of the patients were independent (mRS 0-2). There are many reasons that can explain the poor functional outcomes in our patients; one of them is the decrease rates of thrombolysis and the co-infection with COVID-19. The increased stroke severity at admission in COVID-19 associated stroke patients compared with the non-COVID-19 cohort may explain the worse outcomes. In the global COVID-19 registry, they found 51% of the patients had severe disability at discharge and patients with COVID-19 had higher risk of severe disability and death compared with patients with no COVID19 (27,28,29).

The overall mortality found in our study was high (40.6%) and consistent with some international cohorts such as those carried out in Wuhan and Philadelphia where they report a mortality rate of 54.5% and 39.29% respectively (21). In the subgroup of patients with ischemic stroke, we reported a mortality of 36.6% similar to that reported in The Global COVID-19 Stroke Registry in which information was collected from 28 sites in 16 countries reporting a mortality of 27.6% (29).

Regarding risk factors, we found that age, comorbidities (arterial hypertension and chronic kidney disease) and stroke severity are factors associated with mortality in patients with stroke and COVID-19, as proposed in a study as a phenotype clinical associated with high in-hospital mortality (30). In addition, an association was found between mortality and pro-inflammatory markers (D-dimer and ferritin), which are early markers of severity in COVID-19 (31). The authors propose the need for reorganization strategies of the care system and thus be able to direct a differentiated management in these patients with risk factors for mortality.

There are widely studied pro-inflammatory and hypercoagulability biomarkers that determine a worse prognosis in general in patients with COVID-19 infection (32). In the present study, an association of severe lymphopenia (<500 lymphocytes) and D-dimer > 1 gr / dl (Table 5) was found with greater disability at medical discharge in patients with stroke and COVID-19, these same markers have also been related to a higher mortality rate (table 4). It has been proposed that the inflammatory process and exaggerated immune response can precipitate destabilization of atherosclerotic plaques causing acute thromboembolic events in people with chronic atherosclerosis, and also a high level of proinflammatory cytokines, such as IL-6 whose action is widely recognized in the called "cytokine storm", are associated with greater infarction and poor clinical outcome. All these factors could be associated with more serious cerebrovascular events and therefore cause a greater degree of dependence as evidenced in 37% of our patients in whom a NIHSS

score greater than 15 was found on the emergency room (33).

This study is the first to describe the COVID-19 and stroke patients characteristics and outcomes in two of the most important referral centers in Peru. With the largest hospital capacity in the country, most of the patients had all the laboratory tests and the outcome variables.

However, our findings should be interpreted with caution due to the limitations of our study. First of all, due to the inherent retrospective study design, there is a potential for selection bias. In addition, we only included the social security health system, so the results cannot be extrapolated to the general population.

CONCLUSIONS

This is the largest cohort of stroke and COVID-19 patients reported in Peru. The stroke admissions decrease during the pandemic when compared to 2019. However, greater stroke onset time and ED consultation, stroke severity, and mortality were encountered.

This shows the necessity to educate the population in the early recognition of stroke and the reorganization of acute stroke care in order to carry out a timely treatment to improve the prognosis in these patients.

Sources of funding: None.

Disclosures: None.

*Consent for publication***:** All authors consent to the publication of this manuscript.

Corresponding author:
Marla Gallo-Guerrero
Address: Alameda del Rocio 317. Surco, Lima, Peru
Telephone: 51 989714916
Email address: marla_2g@hotmail.com

REFERENCES

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648

2. Leira EC, Russman AN, Biller J, Brown DL, Bushnell CD, Caso V, et al. Preserving stroke care during the COVID-19 pandemic: Potential issues and solutions. Neurology. 2020; 95(3):124-133. doi: 10.1212/WNL.0000000000009713

3. Merkler AE, Parikh NS, Mir S, et al. Risk of Ischemic Stroke in Patients with Coronavirus Disease 2019 (COVID-19) vs Patients with Influenza. JAMA Neurol. 2020;77(11):1366–1372. doi:10.1001/jamaneurol.2020.2730

4. Dafer RM, Osteraas ND, Biller J. Acute Stroke Care in the Coronavirus Disease 2019 Pandemic. J Stroke Cerebrovasc Dis. 2020; 29(7):104881. doi:10.1016/j.jstrokecerebrovasdis.2020.104881

5. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, et al. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis. 2020; 50(3):587-595. doi: 10.1007/s11239-020-02228-y

6. Rodriguez F, Solomon N, de Lemos JA, Das SR, Morrow DA, Bradley SM, et al. Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry. Circulation. 2021; 143(24): 2332-2342. doi: 10.1161/CIRCULATIONAHA.120.052278

7. Escalera-Antezana JP, Lizon-Ferrufino NF, Maldonado-Alanoca A, Alarcon-De-la-Vega G, Alvarado-Arnez LE, Balderrama-Saavedra MA, et al. Risk factors for mortality in patients with Coronavirus Disease 2019 (COVID-19) in Bolivia: An analysis of the first 107 confirmed cases. Infez Med. 2020;28(2):238-242.

8. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis. *Int J Stroke*. 2021;16(2):137-149. doi:10.1177/1747493020972922

9. The Economist. Tracking covid-19 excess deaths across countries. The Economist; 2021. (Accessed Feb 4, 2022) Available at: https://www.economist.com/graphic-detail/coronavirus-excess-deaths-tracker

10. Baracchini C, Pieroni A, Viaro F, Cianci V, Cattelan AM, Tiberio I, et al. Acute stroke management pathway during Coronavirus-19 pandemic. Neurol Sci 2020;41(5):1003-100

11. Markus HS, Brainin M. COVID-19 and stroke-A global World Stroke Organization perspective. Int J Stroke. 2020;15(4):361-364. doi: 10.1177/1747493020923472

12. Zhao J, Li H, Kung D, Fisher M, Shen Y, Liu R. Impact of the COVID-19 Epidemic on Stroke Care and Potential Solutions. Stroke. 2020;51(7):1996-2001. doi: 10.1161/STROKEAHA.120.030225.

13. Derraz I. Stroke Health Care Use and COVID-19. AJNR Am J Neuroradiol. 2020; 41(6): E36. doi: 10.3174/ajnr.A6563

14. Siegler JE, Cardona P, Arenillas JF, Talavera B, Guillen AN, Chavarría-Miranda A, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19

Multinational Registry. Int J Stroke. 2021;16(4):437-447. doi: 10.1177/1747493020959216

15. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147. doi: 10.1016/j.thromres.2020.04.013

16. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. doi: 10.1016/j.thromres.2020.04.024

17. Ghannam M, Alshaer Q, Al-Chalabi M, Zakarna L, Robertson J, Manousakis G. Neurological involvement of coronavirus disease 2019: a systematic. Review. J Neurol. 2020; 1: 1–19. doi: 10.1007/s00415-020-09990-2

18. Zakeri A, Jadhav AP, Sullenger BA, Nimjee SM. Ischemic stroke in COVID-19-positive patients: an overview of SARS-CoV-2 and thrombotic mechanisms for the neurointerventionalist. J Neurointerv Surg. 2021;13(3):202-206. doi: 10.1136/neurintsurg-2020-016794

19. Soto-Cámara R, González-Bernal JJ, González-Santos J, Aguilar-Parra JM, Trigueros R, López-Liria R. Knowledge on Signs and Risk Factors in Stroke Patients. J Clin Med. 2020;9(8):2557. doi:10.3390/jcm9082557

20. Fridman S, Bres-Bullrich M, Jimenez-Ruiz A, Costantini P, Shah P, Just C, et al. Stroke risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases. Neurology. 2020;95(24):e3373-e3385. doi: 10.1212/WNL.0000000000010851

21. Rothstein A, Oldridge O, Schwennesen H, Do D, Cucchiara BL. Acute Cerebrovascular Events in Hospitalized COVID-19 Patients. Stroke. 2020;51(9):e219-e222. doi: 10.1161/STROKEAHA.120.030995

22. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and Stroke in a New York Healthcare System. Stroke. 2020;51(7):2002-2011. doi: 10.1161/STROKEAHA.120.030335.

23. Martins SO, Mont'Alverne F, Rebello LC, Abud DG, Silva GS, Lima FO, et al. Thrombectomy for Stroke in the Public Health Care System of Brazil. N Engl J Med. 2020;382(24):2316-2326. doi: 10.1056/NEJMoa2000120. PMID: 32521133.

24. Hsiao J, Sayles E, Antzoulatos E, Stanton RJ, Sucharew H, Broderick JP, et al. Effect of COVID-19 on Emergent Stroke Care: A Regional Experience. Stroke. 2020;51(9):e2111-e2114. doi: 10.1161/STROKEAHA.120.030499

25. Plumereau C, Cho TH, Buisson M, Amaz C, Cappucci M, Derex L, et al. Effect of the COVID-19 pandemic on acute stroke reperfusion therapy: data from the Lyon Stroke Center Network. J Neurol. 2021;268(7):2314-2319. doi: 10.1007/s00415-020-10199-6

26. Vences MA, Pareja-Ramos JJ, Otero P, Veramendi-Espinoza LE, Vega-Villafana M, Mogollón-Lavi J, et al. Factors associated with mortality in patients hospitalized with COVID-19: A prospective cohort in a Peruvian national referral hospital. Medwave. 2021;21(6):e8231. doi: 10.5867/medwave.2021.06.8231

27. Pranata R, Huang I, Lim MA, Wahjoepramono EJ, July J. Impact of cerebrovascular and cardiovascular diseases on mortality and severity of COVID-19-systematic review, meta-analysis, and meta-regression. J Stroke Cerebrovasc Dis. 2020; 29(8):104949. doi:10.1016/j.jstrokecerebrovasdis.2020.104949

28. Jain R, Young M, Dogra S, Kennedy H, Nguyen V, Jones S, et al. COVID-19 related neuroimaging findings: A signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci. 2020;414:116923. doi: 10.1016/j.jns.2020.116923

29. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: A systematic review and meta-analysis. Int J Stroke. 2021;16(2):137-149. doi:10.1177/1747493020972922

30. Ntaios G, Michel P, Georgiopoulos G, Guo Y, Li W, Xiong J, et al. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry. Stroke. 2020;51(9):e254-e258. doi: 10.1161/STROKEAHA.120.031208

31. Rothstein A, Oldridge O, Schwennesen H, Do D, Cucchiara BL. Acute Cerebrovascular Events in Hospitalized COVID-19 Patients. Stroke. 2020; 51(9):e219-e222. doi:10.1161/STROKEAHA.120.030995

32. Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021;26(3):107-108. doi: 10.1136/bmjebm-2020-111536.

33. Marta-Enguita J, Corroza-Laviñeta J, Ostolaza A. Risk factors and severity predictors in COVID-19 hospitalized patients: Analysis of 52 patients: Factores de riesgo y predictores de gravedad en pacientes hospitalizados por COVID-19: análisis de 52 casos. Med Clin (Engl Ed). 2020;155(8):360-361. doi: 10.1016/j.medcle.2020.06.018